Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristic MRI pattern in <i>LMNB1</i>-related autosomal dominant leukodystrophy: a case report.

Frontiers in neuroscience·2026
Same author

Facile access to thioethers using sodium thiosulfate as the sulfur surrogate under base-mediated conditions.

Organic & biomolecular chemistry·2026
Same author

Involvement of monocyte/macrophage NLRP3-IL-1β signaling in the pathogenesis of myasthenia gravis.

International immunopharmacology·2026
Same author

Artificial intelligence-driven drug discovery: a new era in therapeutic innovation.

Bioorganic & medicinal chemistry·2026
Same author

Impact of Chemical Quality on High-Throughput in Vitro Assays: A Tox21 Study.

Chemical research in toxicology·2026
Same author

Uremic toxin p‑cresyl sulfate enhances the calcification of aortic valvular interstitial cells via klotho/sirtuin‑1 signaling.

Molecular medicine reports·2026
Same journal

PSDTA: An Approach to Drug-Target Binding Affinity Prediction by Integrating Physicochemical and Structural Information to Reduce Feature Redundancy.

Journal of chemical information and modeling·2026
Same journal

M-JEPA: Predictive Self-Supervised Learning for Molecular Graphs with Scaffold-Shift Evaluation on Tox21.

Journal of chemical information and modeling·2026
Same journal

Advancing Biochemical Molecule Registration, Representation and Search for New Drug Modalities.

Journal of chemical information and modeling·2026
Same journal

A Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug-Hormone Receptor Interactions with Structure-Aware Validation.

Journal of chemical information and modeling·2026
Same journal

Intricate Role of Cholesterol in Membrane Fusion.

Journal of chemical information and modeling·2026
Same journal

tmGNN-XAI: An Explainable Graph Neural Network Tool for Predicting Electronic Properties of Transition Metal Complexes from SMILES.

Journal of chemical information and modeling·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

Consensus Pharmacological Interactions for PLK2 Inhibitor Identification in Colorectal Cancer Treatment.

Yi-Wen Wu1, Chun-Lin Yang1, Tony Eight Lin1,2

  • 1Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

Journal of Chemical Information and Modeling
|December 17, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed a new drug discovery model to identify Polo-like kinase 2 (PLK2) inhibitors for colorectal cancer (CRC). A novel compound, 8012-3246, showed potent anti-cancer activity and selectivity, offering a promising therapeutic strategy.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.6K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.6K

Related Experiment Videos

Last Updated: Jan 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.6K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.6K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Polo-like kinase 2 (PLK2) is crucial in cellular stress, redox regulation, and tumor progression.
  • Elevated PLK2 in colorectal cancer (CRC) correlates with chemoresistance and poor prognosis, making it a therapeutic target.

Purpose of the Study:

  • To develop a structure-based drug discovery strategy for identifying novel PLK2 inhibitors.
  • To evaluate the therapeutic potential of identified PLK2 inhibitors in CRC models.

Main Methods:

  • Developed a consensus model incorporating pharmacological interactions from PLK2 structures to enhance virtual screening.
  • Screened the ChemDiv compound library and identified novel PLK2 inhibitors.
  • Performed structure-activity relationship (SAR) analysis and in vitro assays to evaluate compound potency, cytotoxicity, and antiproliferative effects.

Main Results:

  • The consensus model improved virtual screening hit rates (ROC-AUC from 0.906 to 0.930).
  • Identified two novel PLK2 inhibitors with submicromolar activity; 8012-3246 demonstrated potent cytotoxicity and antiproliferative effects in CRC cell lines.
  • 8012-3246 exhibited high selectivity for PLK2 and inhibited GSK3β phosphorylation, a key downstream effector.

Conclusions:

  • Pharmacological consensus modeling is effective for identifying novel PLK2 inhibitors.
  • PLK2 inhibition represents a promising therapeutic strategy for colorectal cancer treatment.